Sacubitril/Valsartan in Resistant Hypertension

Status Recruiting

Clinical Trial Summary

The present study aims to evaluate the antihypertensive effect of sacubitril/valsartan in patients with resistant hypertension compared to the use of recommended and optimized antihypertensive therapy, through a randomized clinical trial, over 12 weeks.

Clinical Trial Description

Worldwide, millions of people are affected by the arterial hypertension system (SAH), so that the presence of resistant hypertension (RH) significantly influences a high cardiovascular morbidity and mortality compared to those with controlled SAH, thus corroborating the need for the development of agents antihypertensive drugs with favorable efficacy and safety profiles. It is known that they are currently using the combined therapy recommended for this group of patients, among them, a significant portion of individuals with RH are unable to achieve the goal of BP control (>140/90 mmHg) even though in regular use, being subject to the greatest risk of cardiovascular outcomes and morbidity and mortality. Approved by the FDA for use in heart failure with reduced ejection fraction with beneficial effects on morbidity and mortality, identified in previous studies, the sacubitril/valsartan molecule (LCZ696) or Entresto® is a molecular complex composed of the sacubitril prodrug activated after ingestion in sacubitrilate - neprilysin inhibitor - associated with valsartan, an angiotensin II type-1 (AT1) receptor antagonist, with vasodilating action, capable of reducing BP, sympathetic tone, with antifibrotic and anti-hypertrophic effects, in addition to natriuresis and diuresis. Considering the knowledge gap to the benefits to LCZ696 in the control of blood pressure in resistant hypertension, the objective of the present study is to evaluate the efficacy (reduction of ambulatory systolic and diastolic blood pressure) and safety (adverse events, hospitalization and cardiovascular death) of the use of sacubitril/valsartan in comparison to the antihypertensive therapy recommended and optimized by the current guidelines, in patients diagnosed with RH, over12 weeks, through a randomized clinical trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04637152
Study type	Interventional
Source	Hospital Geral Roberto Santos
Contact
Status	Recruiting
Phase	Phase 2
Start date	November 11, 2020
Completion date	November 11, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03255187` - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution	N/A
Completed	`NCT05997303` - Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction	N/A
Recruiting	`NCT04575194` - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy	Phase 4
Completed	`NCT03918486` - Caretaker vs. Routine Blood Pressure Sphygmomanometer
Completed	`NCT03410342` - The Effects of Types of Fruits and Vegetables on Vascular Function	N/A
Active, not recruiting	`NCT05062161` - Sleep Duration and Blood Pressure During Sleep	N/A
Not yet recruiting	`NCT04087070` - Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
Completed	`NCT03294928` - Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers	N/A
Completed	`NCT03859934` - Metabolic Effects of Melatonin Treatment	Phase 1
Completed	`NCT03997461` - Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device	N/A
Completed	`NCT03290716` - Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China	N/A
Recruiting	`NCT05196048` - Blood Pressure Sensor of Watch-type Device With ECG Technology
Recruiting	`NCT06460233` - Blood Pressure Changes After Bariatric Surgery
Terminated	`NCT03325933` - Resistance Training and Cardiometabolic Health	N/A
Not yet recruiting	`NCT06405880` - Pharmacist Case Finding and Intervention for Vascular Prevention Trial	N/A
Completed	`NCT02924454` - Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.	Phase 4
Completed	`NCT02451059` - Reducing Socioeconomic Disparities in Health at Pediatric Visits	N/A
Active, not recruiting	`NCT02670967` - Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials	N/A
Completed	`NCT02239744` - Intervention Study on the Health Impact of Air Filters in Chinese Adults	N/A
Completed	`NCT02271633` - Nitrate Supplementation; Source	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Sacubitril/Valsartan in Resistant Hypertension — HEVA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms